Posted by Michael Wonder on 02 May 2023
Trastuzumab deruxtecan: benefits also in HER2 low breast cancer
2 May 2023 - For patients with advanced HER2 low breast cancer, IQWiG sees an additional benefit that is partly considerable and partly significant.
IQWiG sees a hint of a significant added benefit of trastuzumab deruxtecan compared to therapy according to medical prescription for patients without visceral disease and a hint of a significant added benefit for patients with visceral disease. Advantages in overall survival are decisive for this positive assessment.
